S&P Global Ratings

View Analyst
Contact Information

Japan-Based Takeda's U.S. Dollar-Denominated Unsecured Notes Rated 'BBB+'

    TOKYO (S&P Global Ratings) June 28, 2024--S&P Global Ratings today said it has assigned its 'BBB+' long-term issue credit rating to Takeda Pharmaceutical Co. Ltd.'s (BBB+/Stable/A-2) unsecured notes.

    The issue credit rating is equivalent to our long-term issuer credit rating on Takeda, a Japan-based pharmaceutical company. This is because given the priority of payment of the notes among Takeda's financial obligations, we see a limited possibility of the noteholders being significantly disadvantaged relative to other lenders, including lenders to its subsidiaries.

    The notes have minimal impact on Takeda's credit quality, even though the total issuance is large. This is because the entire amount to be raised through the notes will be used to refinance existing interest-bearing debt. In our view, the notes will help diversify and extend the maturities of Takeda's debt.

    Our rating on Takeda mainly reflects its business strengths including its strong business position in branded pharmaceuticals, diversified product portfolio, and enhanced late-stage development pipeline.

    On the other hand, we expect key measures of Takeda's cash flow to remain slightly weak for the rating on the company. We estimate that at the end of March 2024 the company's debt-to-EBITDA ratio had deteriorated to slightly above 4x, the threshold for considering a downgrade, due mainly to lower revenues from loss of exclusivity (LOE) of patents on some major drugs, expenditures to strengthen its development pipeline, and the effects on debt of yen depreciation. The ratio was 3.3x at the end of March 2023. Although the company is working to restore profitability and financial strength through business restructuring, we expect the ratio may remain slightly above 4x at the end of fiscal 2024 (ending March 31, 2025) due to remaining impact of the LOE during the fiscal year.

    Related Criteria

    Ratings List

    Ratings List

    NEW RATING
    TAKEDA PHARMACEUTICAL CO. LTD.
    ISSUE RATING

    $1,100 million; 10 years; due July 5, 2034; 5.300%

    BBB+

    $800 million; 20 years; due July 5, 2044; 5.650%

    BBB+

    $600 million; 30 years; due July 5, 2054; 5.650%

    BBB+

    $500 million; 40 years; due July 5, 2064; 5.800%

    BBB+


    Certain terms used in this report, particularly certain adjectives used to express our view on rating relevant factors, have specific meanings ascribed to them in our criteria, and should therefore be read in conjunction with such criteria. Please see Ratings Criteria at www.spglobal.com/ratings for further information. Complete ratings information is available to RatingsDirect subscribers at www.capitaliq.com. All ratings affected by this rating action can be found on S&P Global Ratings' public website at www.spglobal.com/ratings.

    European Endorsement Status
    Global-scale credit rating(s) issued by S&P Global Ratings’ affiliates based in the following jurisdictions [To read more, visit Endorsement of Credit Ratings] have been endorsed into the EU and/or the UK in accordance with the relevant CRA regulations. Note: Endorsements for U.S. Public Finance global-scale credit ratings are done per request. To review the endorsement status by credit rating, visit the spglobal.com/ratings website and search for the rated entity.

    No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of Standard & Poor’s Financial Services LLC or its affiliates (collectively, S&P). The Content shall not be used for any unlawful or unauthorized purposes. S&P and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an “as is” basis. S&P PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

    Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P does not act as a fiduciary or an investment advisor except where registered as such. While S&P has obtained information from sources it believes to be reliable, S&P does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives. Rating-related publications may be published for a variety of reasons that are not necessarily dependent on action by rating committees, including, but not limited to, the publication of a periodic update on a credit rating and related analyses.

    To the extent that regulatory authorities allow a rating agency to acknowledge in one jurisdiction a rating issued in another jurisdiction for certain regulatory purposes, S&P reserves the right to assign, withdraw or suspend such acknowledgment at any time and in its sole discretion. S&P Parties disclaim any duty whatsoever arising out of the assignment, withdrawal or suspension of an acknowledgment as well as any liability for any damage alleged to have been suffered on account thereof.

    S&P keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain business units of S&P may have information that is not available to other S&P business units. S&P has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

    S&P may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P reserves the right to disseminate its opinions and analyses. S&P's public ratings and analyses are made available on its Web sites, www.spglobal.com/ratings (free of charge), and www.ratingsdirect.com(subscription), and may be distributed through other means, including via S&P publications and third-party redistributors. Additional information about our ratings fees is available at www.spglobal.com/usratingsfees.

    Any Passwords/user IDs issued by S&P to users are single user-dedicated and may ONLY be used by the individual to whom they have been assigned. No sharing of passwords/user IDs and no simultaneous access via the same password/user ID is permitted. To reprint, translate, or use the data or information other than as provided herein, contact S&P Global Ratings, Client Services, 55 Water Street, New York, NY 10041; (1) 212-438-7280 or by e-mail to: research_request@spglobal.com.



    Contact the analysts: